NexusTrade Loading NexusTrade… Taking too long? Reload this page

About Evolus, Inc. Common Stock (EOLS)

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Ticker
EOLS
Exchange
XNAS
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Company profile updated October 11, 2026.

Stored market snapshot

As of October 9, 2026. Daily closing data may differ from the live quote shown in the dashboard.

Stored daily close (USD)
$7.73
Company market capitalization (USD)
$510,569,901.2

Research EOLS

Compare the company’s price history and fundamentals in the dashboard. Explore disclosed trading and ownership activity in these research collections: